TGTX · TG Therapeutics Inc
United States · RS rating 97 · As of 2026-11-03
| Price | 60.75 USD |
|---|---|
| 1-day change | +1.3% |
| RS rating (overall / 1M / 3M / 12M) | 97 / 86 / 90 / 91 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 52 / 77 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -94.2% |
| Sales growth Q/Q | +19.1% |
| Distance from 52-week high | +0.7% |
| Market cap (USD) | $5.9B |